{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:38:58Z","timestamp":1769272738665,"version":"3.49.0"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"15","funder":[{"DOI":"10.13039\/501100008990","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2018RC020"],"award-info":[{"award-number":["2018RC020"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2018KY024"],"award-info":[{"award-number":["2018KY024"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802995"],"award-info":[{"award-number":["81802995"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,11,27]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy\nwith a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional\nstandards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy\nfor resectable disease with or without chemotherapy, and\/or radiation therapy. The mechanism of carcinogenesis\nhas not been fully elucidated, although approximately 80% of cases can still be linked to\nasbestos exposure. The tumor immune microenvironment (TME) has been proven to play an important\nrole in MPM pathogenesis and treatment outcomes. Several molecular pathways have been implicated\nin the MPM tumor microenvironment, such as angiogenesis, apoptosis, cell cycle regulation, and\nstromal processes. Immunotherapy has already shown promising results in other thoracic solid tumors,\nsuch as non-small-cell lung cancer (NSCLC). However, immunotherapy has shown less convincing\nresults in MPM than in melanoma and NSCLC. A multicenter, randomized trial (DETERMINE)\nproved that immune checkpoint inhibition using tremelimumab, an anti-cytotoxic T lymphocyteassociated\nprotein 4 (CTLA-4) antibody, failed to improve median overall survival. Therefore, it is\nimportant to explore the relationship between the characteristics of the tumor microenvironment and\nimmunotherapy. Here, we review the heterogeneity of the TME and the progress in the understanding\nof the immune microenvironment and immunotherapy in MPM to explore the mechanisms of resistance\nto immunotherapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200719011234","type":"journal-article","created":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T10:38:54Z","timestamp":1595155134000},"page":"1606-1612","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-9671","authenticated-orcid":true,"given":"Lei","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Thoracic Radiotherapy, (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-ling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Min","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"Woolhouse I.","year":"2018","unstructured":"Woolhouse I.; Bishop L.; Darlison L.; British thoracic society guideline for the investigation and management of malignant pleural mesothelioma. Thorax 2018,73(Suppl. 1),i1-i30","journal-title":"Thorax"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"Zalcman G.","year":"2016","unstructured":"Zalcman G.; Mazieres J.; Margery J.; French cooperative thoracic intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016,387(10026),1405-1414","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2217\/fon.12.14","volume":"8","author":"Grosso F.","year":"2012","unstructured":"Grosso F.; Scagliotti G.V.; Systemic treatment of malignant pleural mesothelioma. Future Oncol 2012,8(3),293-305","journal-title":"Future Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","volume":"41","author":"Panou V.","year":"2015","unstructured":"Panou V.; Vyberg M.; Weinreich U.M.; Meristoudis C.; Falkmer U.G.; R\u00f8e O.D.; The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev 2015,41(6),486-495","journal-title":"Cancer Treat Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","volume":"10","author":"Travis W.D.","year":"2015","unstructured":"Travis W.D.; Brambilla E.; Burke A.P.; Marx A.; Nicholson A.G.; Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol 2015,10(9),1240-1242","journal-title":"J Thorac Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","volume":"76","author":"Jahan T.","year":"2012","unstructured":"Jahan T.; Gu L.; Kratzke R.; Vatalanib in malignant mesothelioma: a phase II trial by the cancer and leukemia group B (CALGB 30107). Lung Cancer 2012,76(3),393-396","journal-title":"Lung Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","volume":"18","author":"Carbone M","year":"2012","unstructured":"Carbone M; Yang H.; Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clinical cancer research : an official journal of the american association for cancer research 2012,18(3),598-604","journal-title":"Clinical cancer research : an official journal of the american association for cancer research"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00262-011-1103-6","volume":"60","author":"Bograd A.J.","year":"2011","unstructured":"Bograd A.J.; Suzuki K.; Vertes E.; Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011,60(11),1509-1527","journal-title":"Cancer Immunol Immunother"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1750-2659.2011.00230.x","volume":"5","author":"Jhung M.A.","year":"2011","unstructured":"Jhung M.A.; Davidson H.; McIntyre A.; Preliminary results of 2009 pandemic influenza surveillance in the United States using the aggregate hospitalization and death reporting activity. Influenza Other Respir Viruses 2011,5(5),321-327","journal-title":"Influenza Other Respir Viruses"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/jcp.22724","volume":"227","author":"Carbone M.","year":"2012","unstructured":"Carbone M.; Ly B.H.; Dodson R.F.; Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012,227(1),44-58","journal-title":"J Cell Physiol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","volume":"27","author":"Hegmans J.P.","year":"2006","unstructured":"Hegmans J.P.; Hemmes A.; Hammad H.; Boon L.; Hoogsteden H.C.; Lambrecht B.N.; Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006,27(6),1086-1095","journal-title":"Eur Respir J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coph.2014.06.007","volume":"17","author":"Hegmans J.P.","year":"2014","unstructured":"Hegmans J.P.; Aerts J.G.; Immunomodulation in cancer. Curr Opin Pharmacol 2014,17,17-21","journal-title":"Curr Opin Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","volume":"182","author":"Mossman B.T.","year":"2013","unstructured":"Mossman B.T.; Shukla A.; Heintz N.H.; Verschraegen C.F.; Thomas A.; Hassan R.; New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 2013,182(4),1065-1077","journal-title":"Am J Pathol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"Yap T.A.","year":"2017","unstructured":"Yap T.A.; Aerts J.G.; Popat S.; Fennell D.A.; Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 2017,17(8),475-488","journal-title":"Nat Rev Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/35077241","volume":"17411","author":"Liotta L.A.","year":"2001","unstructured":"Liotta L.A.; Kohn E.C.; The microenvironment of the tumour-host interface. Nature 2001,17411(6835),375-379","journal-title":"Nature"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","volume":"75","author":"Lo A.","year":"2015","unstructured":"Lo A.; Wang L.S.; Scholler J.; Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer Res 2015,75(14),2800-2810","journal-title":"Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1101\/sqb.2005.70.007","volume":"70","author":"Egeblad M.","year":"2005","unstructured":"Egeblad M.; Littlepage L.E.; Werb Z.; The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 2005,70,383-388","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","volume":"179","author":"Li Q.","year":"2011","unstructured":"Li Q.; Wang W.; Yamada T.; Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network. Am J Pathol 2011,179(3),1483-1493","journal-title":"Am J Pathol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"Wang L.C.","year":"2014","unstructured":"Wang L.C.; Lo A.; Scholler J.; Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014,2(2),154-166","journal-title":"Cancer Immunol Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fimmu.2017.00086","volume":"8","author":"Elliott LA","year":"2017","unstructured":"Elliott LA; Doherty GA; Sheahan K; Ryan EJ; Human tumorinfiltrating myeloid cells Phenotypic and functional diversity front immunol 2017,8,86","journal-title":"Phenotypic and functional diversity front immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/1471-2407-10-464","volume":"10","author":"Veltman J.D.","year":"2010","unstructured":"Veltman J.D.; Lambers M.E.; van Nimwegen M.; COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010,10,464","journal-title":"BMC Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1002\/cncr.26143","volume":"117","author":"Burt B.M.","year":"2011","unstructured":"Burt B.M.; Rodig S.J.; Tilleman T.R.; Elbardissi A.W.; Bueno R.; Sugarbaker D.J.; Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011,117(22),5234-5244","journal-title":"Cancer"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106742","volume":"9","author":"Cornelissen R.","year":"2014","unstructured":"Cornelissen R.; Lievense L.A.; Maat A.P.; Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS One 2014,9(9)","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.lungcan.2015.03.013","volume":"88","author":"Cornelissen R.","year":"2015","unstructured":"Cornelissen R.; Lievense L.A.; Robertus J.L.; Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. Lung Cancer 2015,88(3),332-337","journal-title":"Lung Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","volume":"11","author":"Ch\u00e9n\u00e9 A.L.","year":"2016","unstructured":"Ch\u00e9n\u00e9 A.L.; d\u2019Almeida S.; Blondy T.; Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J Thorac Oncol 2016,11(10),1765-1773","journal-title":"J Thorac Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"Spranger S.","year":"2015","unstructured":"Spranger S.; Bao R.; Gajewski T.F.; Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 2015,523(7559),231-235","journal-title":"Nature"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","volume":"8","author":"Belderbos R.A.","year":"2019","unstructured":"Belderbos R.A.; Baas P.; Berardi R.; A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl Lung Cancer Res 2019,8(3),280-285","journal-title":"Transl Lung Cancer Res"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1474318","volume":"7","author":"Noordam L.","year":"2018","unstructured":"Noordam L.; Kaijen M.E.H.; Bezemer K.; Low-dose cyclophosphamide depletes circulating na\u00efve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. OncoImmunology 2018,7(12)","journal-title":"OncoImmunology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1165\/rcmb.2012-0134OC","volume":"49","author":"Kumagai-Takei N.","year":"2013","unstructured":"Kumagai-Takei N.; Nishimura Y.; Maeda M.; Effect of asbestos exposure on differentiation of cytotoxic T lymphocytes in mixed lymphocyte reaction of human peripheral blood mononuclear cells. Am J Respir Cell Mol Biol 2013,49(1),28-36","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/492608","author":"Matsuzaki H.","year":"2012","unstructured":"Matsuzaki H.; Maeda M.; Lee S.; Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol 2012","journal-title":"J Biomed Biotechnol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1165\/rcmb.2010-0213OC","volume":"45","author":"Maeda M.","year":"2011","unstructured":"Maeda M.; Nishimura Y.; Hayashi H.; Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2. Am J Respir Cell Mol Biol 2011,45(3),470-479","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/cmi.2017.148","volume":"15","author":"Xu W.","year":"2018","unstructured":"Xu W.; Hi\u1ebfu T.; Malarkannan S.; Wang L.; The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol 2018,15(5),438-446","journal-title":"Cell Mol Immunol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/cmi.2017.143","volume":"15","author":"Zhai L.","year":"2018","unstructured":"Zhai L.; Ladomersky E.; Lenzen A.; IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol 2018,15(5),447-457","journal-title":"Cell Mol Immunol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nri1592","volume":"5","author":"Banchereau J.","year":"2005","unstructured":"Banchereau J.; Palucka A.K.; Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005,5(4),296-306","journal-title":"Nat Rev Immunol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/ijc.32363","volume":"145","author":"Sottile R.","year":"2019","unstructured":"Sottile R.; Tannazi M.; Johansson M.H.; Cristiani C.M.; Calabro L.; Ventura V.; NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy. Int J Cancer 2019,145(8),2238-2248","journal-title":"Int J Cancer"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"Wang X.","year":"2016","unstructured":"Wang X.; Rivi\u00e8re I.; Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 2016,3,16015","journal-title":"Mol Ther Oncolytics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Zhang Q.","year":"2018","unstructured":"Zhang Q.; Bi J.; Zheng X.; Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol 2018,19(7),723-732","journal-title":"Nat Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/cmi.2017.10","volume":"15","author":"Liu Y.","year":"2018","unstructured":"Liu Y.; Zheng J.; Liu Y.; Uncompromised NK cell activation is essential for virus-specific CTL activity during acute influenza virus infection. Cell Mol Immunol 2018,15(9),827-837","journal-title":"Cell Mol Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"Miyara M.","year":"2009","unstructured":"Miyara M.; Yoshioka Y.; Kitoh A.; Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009,30(6),899-911","journal-title":"Immunity"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00262-012-1360-z","volume":"62","author":"McCoy M.J.","year":"2013","unstructured":"McCoy M.J.; Nowak A.K.; van der Most R.G.; Dick I.M.; Lake R.A.; Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother 2013,62(3),529-539","journal-title":"Cancer Immunol Immunother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","volume":"135","author":"Anraku M.","year":"2008","unstructured":"Anraku M.; Cunningham K.S.; Yun Z.; Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008,135(4),823-829","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"Wei S.C.","year":"2017","unstructured":"Wei S.C.; Levine J.H.; Cogdill A.P.; Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell 2017,170(6),1120-1133.e17","journal-title":"Cell"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1464-410X.2009.09189.x","volume":"34","author":"\u675c\u96ea\u6885","year":"2018","unstructured":"\u675c\u96ea\u6885 ; \u674e\u946b\u5b9d ; \u4e8e\u6d0b ; \u5b59\u840d\u840d ; \u9ad8\u9896 ; \u660c\u7ea2 ; \u6076\u6027\u95f4\u76ae\u7624\u4e2dPD-1\u548cPD-L1\u7684\u8868\u8fbe\u53ca\u610f\u4e49 %J \u4e34\u5e8a\u4e0e\u5b9e\u9a8c\u75c5\u7406\u5b66\u6742\u5fd7 %J  Chinese Journal of Clinical and Experimental Pathology 2018,34(12),1348-1352","journal-title":"Chinese Journal of Clinical and Experimental Pathology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"Pasello G.","year":"2018","unstructured":"Pasello G.; Zago G.; Lunardi F.; Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol 2018,29(5),1258-1265","journal-title":"Ann Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","volume":"13","author":"Metaxas Y.","year":"2018","unstructured":"Metaxas Y.; Rivalland G.; Mauti L.A.; Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol 2018,13(11),1784-1791","journal-title":"J Thorac Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ajco.12788","volume":"14","author":"Nguyen B.H.","year":"2018","unstructured":"Nguyen B.H.; Montgomery R.; Fadia M.; Wang J.; Ali S.; PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac J Clin Oncol 2018,14(1),69-73","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","volume":"20","author":"Brosseau S.","year":"2019","unstructured":"Brosseau S.; Danel C.; Scherpereel A.; Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: A series of 214 cases from the Bio-MAPS cohort. Clin Lung Cancer 2019,20(5),e564-e575","journal-title":"Clin Lung Cancer"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.lungcan.2020.02.006","volume":"142","author":"Bronte G.","year":"2020","unstructured":"Bronte G.; Delmonte A.; Burgio M.A.; Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. Lung Cancer 2020,142,47-50","journal-title":"Lung Cancer"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"98575","DOI":"10.1172\/jci.insight.98575","volume":"3","author":"Lee H.S.","year":"2018","unstructured":"Lee H.S.; Jang H.J.; Choi J.M.; Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight 2018,3(7),98575","journal-title":"JCI Insight"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183882","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183882\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T04:58:02Z","timestamp":1625201882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183882\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,11,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200719011234","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}